| abstract |
The present invention relates to recombinant endolysin ClyC having a high killing ability against Staphylococcus aureus, and more particularly, to Staphylococcus aureus compared to conventional endolysin. It relates to a recombinant endolysin ClyC having a biofilm removal ability. The present invention can provide a recombinant endolysin ClyC that has been proven to have effective mycelial killing ability even in milk and real animal blood and serum conditions, which are often infected with Staphylococcus aureus. In addition, unlike the parent endolysin, it exhibits stable antibacterial activity of 95% of its maximum activity even with a slight heat, so it can be used in food, medicine and pharmaceutical industries. |